Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567671 · ClinicalTrials.gov registry record · Phase 2
Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia
A Phase 2 study of Corneal Ectasia and Progressive Keratoconus, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT00567671 is a Phase 2 study of Corneal Ectasia and Progressive Keratoconus that has completed, run by Emory University. The registered enrollment target is 160 participants, below the 283-participant average among 3 other Corneal Ectasia trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00567671, a Phase 2 study of Corneal Ectasia and Progressive Keratoconus, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, randomized, single site study to determine the safety and effectiveness of performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with corneal ectasia or progressive keratoconus.
Conditions Studied
Interventions
- PROCEDURE Corneal collagen
- PROCEDURE Sham comparator
Study Locations (1)
Georgia
- Woolfson Eye Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00567671
The ClinicalTrials.gov registry entry for NCT00567671 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 3 other Corneal Ectasia trials with a reported enrollment target (43% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Corneal Ectasia appearing as the primary indexed condition, and to 2 interventions - of which Corneal collagen is the first listed.
NCT00567671 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT00567671 about?
NCT00567671 is a clinical study titled "Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia". Prospective, randomized, single site study to determine the safety and effectiveness of performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with corneal ectasia or progressive keratoconus.
What is the current status of trial NCT00567671?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2007-12. Estimated completion is 2010-06.
What conditions does trial NCT00567671 study?
This clinical trial studies the following conditions: Corneal Ectasia, Progressive Keratoconus.
What interventions are being tested in trial NCT00567671?
The interventions under investigation include: Corneal collagen (PROCEDURE), Sham comparator (PROCEDURE).
Who is sponsoring clinical trial NCT00567671?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00567671 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Ectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia
RECRUITING · Phase 2
-
Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism
ACTIVE NOT RECRUITING · NA
-
Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.